Skip to main content
  • Boston Scientific Exercises Option to Acquire Farapulse, Inc.

    Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology

    MARLBOROUGH, Mass., June 24, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.  

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details